Potential at a macro level absolutely!
I’m referring to announcements like Philips and Integral that convey potential to generate revenue. It’s time to see some substantial cash flow figures. The IMED agreement had massive potential. All meaningless if the Go-to-Market team can’t monetise the technology. I’d rather have one productive distribution agreement proving the concept clinically and commercially than multiple agreements with potential.
Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2025, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.025(8.62%) |
Mkt cap ! $123.3M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 26.5¢ | $387.4K | 1.414M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 126757 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 1450 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| 4DX (ASX) Chart |